1Chwieduk CM, Keating GM. Paliperidone extended release: a review of its use in the management of schizophrenia[J]. Drugs,2010,70(10) : 1295- 1317.
2de Leon JD, Wynn G, Sandson NB. The pharmacokinetics of paliperidone versus risperidone[J].Psychosomatics, Z010,51 (1):80- 88.
3Si T, Shu L, Si Y, et al. Single-dose pharmaeokineties of paliperidone extended release tablets in healthy Chinese subiects[J].Hum Psychopharmacol,2010,25(5):404- 409.
4Ortega I, Perez- Ruixo JP, Stuyckens K, et al. Modeling the effectiveness of paliperidone ER and olanzapine in schizophrenia: meta-analysis of randomized,controlled clinical trials[J].J Clin Pharmacology,2010,50(3) :293- 310.
5Spina E, Cavallaro R. The pharmacology and safety of paliperidone extended release in the treatment of schizophrenia [J]. Expert Opin Drug Saf,2007,6(6) :651- 662.
6Madhusoodanan S, Zaveri D. Paliperidone use in the elderly [J]. Curr Drug Saf,2010,5(2) :149-152.
7Dolder C. Review: paliperidone reduces symptoms of schizophrenia and schizophrenia like illness [J].Evid Based Ment Health, 2008,11(4) : 114.
8Chang JP, Huang CC,Su KP. Paliperidone overdose in a patient with schizophrenia[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2010,34(2) :418.
9Mantas C, Kalabokis C, Goulia P, et al. Possible neuroleptic malignant syndrome during paliperldone administration: a case report[J]. J Clin Psychopharmacology, 2010,30( 1 ): 89-90.
